New Zealand markets close in 42 minutes

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
54.46-3.24 (-5.62%)
At close: 04:00PM EDT
56.08 +1.62 (+2.97%)
After hours: 06:39PM EDT

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100
https://www.corbuspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees19

Key executives

NameTitlePayExercisedYear born
Dr. Yuval Cohen Ph.D.CEO & Director907.78kN/A1975
Mr. Sean F. Moran CPA, M.B.A.Chief Financial Officer609.28kN/A1958
Ms. Lindsey SmithHead of Corporate Communications & Patient AdvocacyN/AN/AN/A
Ms. Christina BertschHead of Human ResourcesN/AN/AN/A
Dr. Dominic Smethurst M.A., M.D.Chief Medical OfficerN/AN/A1975
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corporate governance

Corbus Pharmaceuticals Holdings, Inc.’s ISS governance QualityScore as of 1 July 2024 is 5. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 4; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.